机器人辅助根治性膀胱切除术后的十年肿瘤学结局:国际机器人膀胱切除术联盟结果
该研究回顾性分析国际机器人膀胱切除术联盟前瞻性数据库中446例10年前或更早接受机器人辅助根治性膀胱切除术的患者,中位年龄67岁,中位随访5年(最长14年)。十年无复发生存率、疾病特异性生存率和总生存率分别为59%、65%和35%,局部复发和远处复发分别见于15%和29%的患者。作者认为长期肿瘤学结局及复发率与开放手术系列似乎相当,晚期疾病分期和阳性手术切缘仍是生存的主要决定因素。
要点
- 十年无复发生存率59%、疾病特异性生存率65%、总生存率35%。
- 中位随访5年时局部复发15%、远处复发29%。
- pT3及以上和pN+患者无复发生存、疾病特异性生存和总生存更差。
核心结论
- 机器人辅助根治性膀胱切除术后的长期肿瘤学结局、复发率和复发模式似乎与开放手术系列相当。
- 晚期疾病分期和阳性手术切缘仍是根治性膀胱切除术后生存的主要决定因素。
研究设计与样本
- 回顾性分析前瞻性国际机器人膀胱切除术联盟数据库。
- 纳入10年前或更早接受机器人辅助根治性膀胱切除术的连续患者446例,中位年龄67岁(IQR 59-76)。
主要发现
- 10%患者接受新辅助化疗,51%发生任何并发症,23%发生高级别并发症,4%在机器人辅助根治性膀胱切除术后3个月内死亡。
- 43%患者疾病为pT3或更高,24%为pN+,7%观察到阳性软组织手术切缘。
- 中位随访5年(IQR 2-10,最长14年)时,局部复发和远处复发分别见于15%和29%的患者。
- 十年无复发生存率、疾病特异性生存率和总生存率分别为59%、65%和35%。
- pT3或更高和pN+疾病患者的无复发生存、疾病特异性生存和总生存更差。
关键数值与推荐
- 十年无复发生存率为59%,疾病特异性生存率为65%,总生存率为35%。
- 中位随访5年时局部复发率为15%,远处复发率为29%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radical cystectomy is the gold standard for nonmetastatic muscle invasive bladder cancer and for refractory nonmuscle invasive disease. Compared to open radical cystectomy, robot-assisted radical cystectomy has been shown to provide comparable early oncologic outcomes and improved perioperative outcomes. However, there is a paucity of data on long-term oncologic outcomes and concerns about a higher incidence of local recurrence after robot-assisted radical cystectomy. We report 10-year oncologic outcomes following robot-assisted radical cystectomy using a multinational database. MATERIALS AND METHODS: We retrospectively reviewed the prospective International Robotic Cystectomy Consortium database. Consecutive patients who underwent robot-assisted radical cystectomy 10 years ago or earlier were included in analysis. Data were reviewed for demographics, and perioperative, pathological and oncologic outcomes. Kaplan-Meier curves were used to depict recurrence-free, disease specific and overall survival. Multivariate stepwise Cox regression models were applied to identify variables associated with recurrence-free, disease specific and overall survival. RESULTS: We identified 446 patients with a median age of 67 years (IQR 59-76). Of the patients 10% received neoadjuvant chemotherapy, 51% experienced any complication, 23% had high grade complications and 4% died within 3 months of robot-assisted radical cystectomy. Disease was pT3 or greater in 43% of patients and pN+ in 24% while a positive soft tissue surgical margin was observed in 7%. At a median followup of 5 years (IQR 2-10, maximum 14) local and distant recurrence had developed in 15% and 29% of patients, respectively. Ten-year recurrence-free, disease specific and overall survival rates were 59%, 65% and 35%, respectively. Patients with pT3 or greater and pN+ disease showed worse recurrence-free, disease specific and overall survival. CONCLUSIONS: Long-term oncologic outcomes, and recurrence rates and patterns after robot-assisted radical cystectomy seem comparable to those in open series. Advanced disease stage and positive surgical margins remain the main determinants of survival after radical cystectomy.
引用
- Hussein AA, Elsayed AS, Aldhaam NA, et al. Ten-Year Oncologic Outcomes Following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. J Urol. 2019. PMID: 31188729. doi:10.1097/JU.0000000000000386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。